Effect of P-glycoprotein Inhibitor (Carvedilol) on Developmental Outcome Methotrexate are Given Alone and in Combination of Pregnant Rats
Article Sidebar
Main Article Content
Abstract
This study was performed according to FDA protocol to evaluate the developmental effects of carvedilol (P-glycoprotein inhibitor), methotrexate (P-glycoprotein substrate) and their combination at therapeutic doses on pregnant rats. Sixty Albino Wistar rats (40 female rats and 20 males) were allocated randomly into four groups orally administered 0.72 mg/kg carvedilol (Cv-treated group [TG]), 0.36 mg/kg methotrexate (MTX-TG), combined doses carvedilol+methotrexate (Cv+MTX-TG), and distilled water (control group) for 2 months in male and 2 weeks in female rats before mating and after copulation, then approval of pregnancy; dosing continued in female groups during pregnancy and lactation periods. Half of the animal groups were euthanized one day before parturition to study prenatal effects, while the other half left for parturition and lactation to study postnatal effect. The results of fertility index recorded in Cv-TG (71.43%), MTX-TG (42.46%) and Cv+MTX-TG (38.47%) was markedly lower than that in control (83.33%) group with lower gestation index was recorded in MTX-TG (80%) and Cv+MTX-TG (60%) than that in Cv-TG (100%) and the control group (100%). The result of resorbed and fetal death recorded a higher percent in Cv-MTX-TG in comparison with MTX-TG and Cv-TG; Cv-MTX-TG fetuses also recorded more anomalies, including hemorrhagic placenta, curved legs, and microcephaly during prenatal period. The postnatal effects showed that the Cv+MTX-TG group recorded a higher decrease in number of pups born, their weight, and increase in number of stillbirths in comparison with methotrexate followed by carvedilol groups in comparison with control group, while the result of viability index recorded (Cv-TG=98.15%, MTX-TG=93.93% and Cv+MTX-TG=76.19%) and lactation index (Cv-TG=77.36%, 83.87% and Cv+MTX-TG=75%). The postnatal anomalies were only recorded in Cv+MTX-TG included skull defect and ulceration, blindness, skin lesion, and alopecia in lactating pups. It is concluded that inhibition of P-gp by carvedilol might increase the placental passage and increase methotrexate concentration in fetal and pups’ tissue with consequence of increase toxic effect of methotrexate both in fetus and pups of Cv+MTX-TG group which might explain the present results of teratogenic study.
Downloads
Article Details
How to Cite
References
Duong A, Steinmaus C, McHale C, Vaughan C, Zhang L. Reproductive and developmental toxicity of formaldehyde: a systematic review. Mutat Res.2011;728(3):118-138. https://doi.org/10.1016/j.mrrev.2011.07.003
Garcia-Bournissen F, Feig DS, Koren G. Maternal-fetal transport of hypoglycaemic drugs. Clin Pharmacokinet. 2003;42(4):303-313. https://doi.org/10.2165/00003088-200342040-00001
Nakamura Y, Ikeda S, Furukawa T, Sumizawa T, Tani A, Akiyama S, et al. Function of P-glycoprotein expressed in placenta and mole. Biochem Biophys Res Commun. 1997;235(3):849–583. https://doi.org/10.1006/bbrc.1997.6855
Chapa JB, Hibbard JU, Weber EM, Abramowicz JS, Verp MS. Prenatal diagnosis of methotrexate embryopathy. Obstet Gynecol.
;101(5 Pt 2):1104-1107.
Stein WD, Cardarelli C, Pastan I, Gottesman MM. Kinetic evidence suggesting that the multidrug transporter differentially handles influx and efflux of its substrates. Mol Pharmacol. 994;45(4):763-772.
Sharma RC, Assaraf YG, Schimke RT. A phenotype conferring selective resistance to lipophilic antifolates in Chinese hamster ovary cells. Cancer Res.1991;51:2949-2959.
Lymperopoulos A, McCrink KA, Brill A. Impact of CYP2D6 genetic variation on the response of the cardiovascular patient to carvedilol and metoprolol. Curr. Drug Metab.2015;17(1):30–36. https://doi.org/10.2174/1389200217666151105125425
Običan S, Scialli AR. Teratogenic exposures. Am J Med Genet C Semin Med Genet. 2011;157C(3):150-169. https://doi.org/10.1002/ajmg.c.30310
Takara K, Sakaeda T, Okumura K. Carvedilol: a new candidate for reversal of MDR1/P-glycoprotein-mediated multidrug resistance. Anti-Cancer Drugs. 2004; 15(4):303–309. https://doi.org/10.1097/00001813-200404000-00001
McNeil JJ, Louis WJ. Clinical pharmacokinetics of labetalol. Clin Pharmacokinet.1984;9(2):157-167. https://doi.org/10.2165/00003088-198409020-00003
Bello AE, Perkins EL, Jay R, Efthimiou P. Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis. Open Access Rheumatol. 2017;9:67-79. https://doi.org/10.2147/OARRR.S131668
Klaassen CD, Amdur MO, Doull T. Cassaret and Doull’s Toxicology: The Basic Science of Poisons (9th Ed.): Macmillan (Ed) Publishing Company, New York. 2019.
Snedecor GW, Cochran WG. Statistical methods. 7th ed. Iowa State Unv. Press., Ames., Iowa, U.S.A. 1980.
Bachmakov I, Werner U, Endress B, Auge D, Fromm MF. Characterization of β-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein. Fundam. Clin. Pharmacol. 2006; 20(3):273–282. https://doi.org/10.1111/j.1472-8206.2006.00408.x
Wessler JD, Grip LT, Mendell J, Giugliano RP. The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol. 2013;61(25):2495-502. https://doi.org/10.1016/j.jacc.2013.02.058
Baris N, Kalkan S, G¨uneri S, Bozdemir V, Guven H. Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference? Eur. J. Clin. Pharmacol.2006; 62(7):535–538. https://doi.org/10.1007/s00228-006-0138-7
El-Ashmawy IM, El-Nahas AF, Bayad AE. Teratogenic and cytogenetic effects of ivermectin and its interaction with P-glycoprotein inhibitor. Res Vet Sci.2011; 90(1):116-23. https://doi.org/10.1016/j.rvsc.2010.05.020
Daud AN, Bergman JE, Bakker MK, Wang H, Kerstjens-Frederikse WS, de Walle HE, et al. P-glycoprotein-mediated drug interactions in pregnancy and changes in the risk of congenital anomalies: A case-reference study. Drug Saf.2015;38(7):651-659. https://doi.org/10.1007/s40264-015-0299-3
Rahi M, Heikkinen T, Härtter S, Hakkola J, Hakala K, Wallerman O, et al. Placental transfer of quetiapine in relation to P-glycoprotein activity. J Psychopharmacol.2007;21: 751-756. https://doi.org/10.1177/0269881106074065
Ponticelli C, Moroni G. Fetal toxicity of immunosuppressive drugs in pregnancy. J Clin Med. 2018;7(12):552. https://doi.org/10.3390/jcm7120552
Myllynen P, Pienimäki P, Vähäkangas K. Human placental perfusion method in the assessment of transplacental passage of antiepileptic drugs. Toxicol Appl Pharmacol. 2005;207(2 Suppl):489-494. https://doi.org/10.1016/j.taap.2005.01.042
Thorne JC, Nadarajah T, Moretti M, Ito S. Methotrexate use in a breastfeeding patient with rheumatoid arthritis. J Rheumatol. 2014;41(11):2332. https://doi.org/10.3899/jrheum.140263
Bateman BT, Patorno E, Desai RJ, Seely EW, Mogun H, Maeda A, et al. Late pregnancy β blocker exposure and risks of neonatal hypoglycemia and bradycardia. Pediatrics. 2016;138(3):e20160731. https://doi.org/10.1542/peds.2016-0731
Hyoun SC, Običan SG, Scialli AR. Teratogen update: methotrexate. Birth Defects Res A Clin Mol Teratol. 2012;94(4):187-207. https://doi.org/10.1002/bdra.23003
Amin FA, Alwan AF. Prenatal Study of testes growth and histological development 2-fetal goat. Iraqi J. Vet. Med. 2010;34(1):177-185. https://doi.org/10.30539/iraqijvm.v34i1.677
Ajayi AF, Akhigbe RE. Staging of the estrous cycle and induction of estrus in experimental rodents: an update. Fertil Res Pract. 2020; 6: 5. https://doi.org/10.1186/s40738-020-00074-3